Udvalget fandt, at fordelene ved Posaconazole SP er større end risiciene ved behandling af invasiv aspergillose, fusariose, coccidioidomykose, chromoblastermykose og mycetom hos patienter, der ikke tåler andre svampemidler, eller hos hvem der ikke er indtrådt bedring efter 7 dages behandling.
The Committee decided that Posaconazole SP’ s benefits are greater than its risks for treatment of invasive aspergillosis, fusariosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients who cannot tolerate other antifungal drugs or have not improved after at least 7 days of treatment.